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Objective:
 
 To determine the cost-effectiveness of initia-
tion of second-line hormone therapy with letrozole in the
treatment of advanced breast cancer in postmenopausal
women in Canada, compared to megestrol acetate.
 
Methods:
 
 A modified Markov model, incorporating
seven health states, was designed to simulate the treat-
ment of patients with advanced breast cancer from sec-
ond-line hormone therapy to death. The model was
constructed with data from a clinical trial, literature
sources, and interviews with breast cancer treatment
experts. Canadian experts provided information on re-
source utilization patterns and local costs were attached
to these resources. The model was used to calculate
mean survival time, time without progression, and total
direct medical costs for patients initiating treatment
with letrozole 2.5 mg or megestrol acetate 160 mg.
 
Results:
 
 The mean survival time and time without pro-
gression for letrozole 2.5 mg patients were 28.3 months
and 19.0 months, respectively, compared to 25.7 months
and 16.5 months for megestrol acetate 160 mg patients.
Total treatment costs for both groups were similar with
the letrozole 2.5 mg group costing $20,068 per patient,
$1061 more than the megestrol acetate 160 mg group
($CAN, 1996). The cost-effectiveness ratio for letrozole
2.5 mg with respect to megestrol was $5051 per year of
life gained. Sensitivity analysis showed that this ratio
was sensitive to variations in the probabilities govern-
ing disease progression.
 
Conclusions:
 
 Advanced breast cancer patients initiating
second-line hormone therapy with letrozole 2.5 mg
have better clinical outcomes than patients receiving
megestrol acetate 160 mg. Furthermore, this benefit
comes at an acceptable cost to the Canadian health care
system.
 
Keywords
 
: advanced breast cancer, Canada, cost-effec-
tiveness ratio, letrozole, Markov modeling.
 
Introduction
 
Breast cancer is the most common malignancy
among women in the developed world, and the
worldwide burden of the disease continues to in-
crease [1,2]. In 1998 in Canada it was estimated
that there would be 19,300 new cases of breast can-
cer diagnosed with 5,300 deaths [3]. The probabil-
ity of developing the disease is highly dependent on
age, with most of the risk apparent after age 50
[1,4]. In Canada the overall lifetime probability of
developing breast cancer is presently 11% and the
risk of dying from the disease is 4.1% [3,5].
Although breast cancer is now recognized as a
systemic disease there is a marked heterogeneity in
progression of the disease [6]; treatment options
are dictated by the size and hormonal status of the
tumor and the presence or absence of metastatic
cancer [7–12]. Patients presenting with locally ad-
vanced or metastatic breast cancer, or those who
develop metastatic disease after initial treatment,
have a high incidence of recurrence [13]. On re-
currence, patients are usually treated with a sec-
ond-line therapy consisting either of chemother-
apy or hormonal therapy. The decision as to the
choice of second-line therapy depends on the first-
line therapy employed and the response of the tu-
mor to this initial therapy [4,14–16].
The overall economic impact of breast cancer is
difficult to assess because of the wide variation in
patient response, the long-term course of disease
in some patients, and different therapeutic ap-
proaches. Nevertheless, several studies have at-
tempted to evaluate the cost of treating the disease
[11,12,17,18] and the cost-effectiveness of screen-
ing programs designed to identify breast cancer
patients at an early stage of the disease [19]. In a
study on advanced breast cancer patients in The
Netherlands, de Koning et al. [20] calculated the
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lifetime treatment costs in 1990 at NLG 34,200
($24,618 CAN) which increased to NLG 42,000
($30,233 CAN) when ambulatory costs were in-
cluded. The major cost driver in treatment was
hospitalization, which was 62% of the total cost
while drug costs were only eight percent of the to-
tal. Other studies have shown that a major deter-
mining factor in the economic burden of advanced
breast cancer is the cost associated with treatment
of disease recurrence [17].
Although the clinical value of new therapeutic
approaches to the treatment of advanced breast
cancer can be demonstrated in clinical trials, it has
become increasingly important to health care deci-
sion-makers that new therapies are shown to pro-
vide cost-effective care. Letrozole is a selective ar-
omatase inhibitor for the second-line management
of advanced breast cancer in postmenopausal
women and the efficacy of the drug has been dem-
onstrated in a clinical trial [21]. The present study
examines how the introduction of this drug would
impact the overall treatment costs associated with
the long-term management of advanced breast
cancer patients in Canada. In the absence of pro-
spective health economic data, the study relies on
decision analytical modeling to project long-term
clinical and economic consequences.
 
Methods
 
Design
 
A semi-Markov process model was constructed to
simulate the course of advanced breast cancer in a
typical patient treated either with letrozole or
megestrol acetate as a second-line hormone ther-
apy [22]. The foundation of the model was data
from a clinical trial and the patient population de-
fined for the model was identical to the patients
recruited for this trial [21]. These patients were
postmenopausal women with advanced breast
cancer who had previously failed first-line anties-
trogen or adjuvant antiestrogen therapy and, at
the time of recruitment, had no rapidly progres-
sive disease. The analysis covered the period be-
tween the initiation of second-line therapy and
death (lifetime model). The effectiveness of treat-
ment was expressed as survival and time without
progression and the model incorporated all rele-
vant economic measures. These included direct
medical resource utilization patterns associated
with outpatient and inpatient care for the treat-
ment of advanced breast cancer. Indirect resources
and costs were not assessed. In the primary analy-
sis costs were discounted at 5% annually while
outcomes were not discounted and the perspective
of the economic assessment was that of the third-
party payer in Canada (the provincial Ministries
of Health).
 
Model
 
This model has already been described in detail by
Nuijten et al. [23]. In brief, a computer software
package (DATA2.6, TreeAge) was used to create
the Markov model, which was designed to incor-
porate seven primary health states: second-line
hormone treatment, third-line hormone treatment,
chemotherapy 1, chemotherapy 2, observational
care, end-stage palliative care, and death. The
model simulated lifetime outcomes for patients
presenting with advanced breast cancer, where the
time period was broken down into cycles of 3
months. This cycle time was chosen because in the
clinical trial patients were assessed at 3-month in-
tervals. The maximum follow-up period of the
model was based on a cut-off point where less
than 1% of the patients would still be alive.
Patients entering the model were randomly as-
signed second-line hormone therapy with either
letrozole 2.5 mg or megestrol acetate 160 mg. At
the end of the first cycle this therapy was assumed
to lead to one of four clinical outcomes: 1) no pro-
gression with severe adverse events; 2) no progres-
sion without severe adverse events; 3) progression
with severe adverse events; or 4) progression without
severe adverse events. In the absence of progression
and adverse events, the patient would likely continue
to receive the same second-line hormone therapy.
However, for the remaining clinical outcomes a pa-
tient would either continue on second-line hormone
therapy or alternatively receive a change in treat-
ment. The possible changes in treatment are shown
in Figure 1, which defines the structure of the letro-
zole arm of the Markov model for this first cycle.
The probability of a particular outcome and the
probabilities defining which treatment the patient
would receive are based on transition probabilities
which are incorporated into the model. Although
Figure 1 only shows a small portion of the com-
plete model, subsequent arms of the model de-
velop in the same manner and the movement of a
patient through the model is dependent on the pres-
ence or absence of disease progression at the end
of each cycle. A schematic diagram of the com-
plete model is shown in Figure 2. The model struc-
ture for megestrol acetate 160 mg is identical to
that for letrozole 2.5 mg. The clinical role of ad-
verse events in initiating a treatment change was
only incorporated into the second-line hormone
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health state and the probability of these events oc-
curring was determined directly from the clinical
trial data (see below) [21]. In succeeding health
states adverse events were not directly incorpo-
rated into the model since the occurrence of these
events could not be determined with any degree of
accuracy from the data sources.
 
Data Collection
 
For the probabilities of clinical outcomes and oc-
currence of adverse events during second-line hor-
mone therapy, data were derived directly from the
clinical trial [21]. A retrospective analysis was
used because the model was developed while the
clinical trial was ongoing. An intent-to-treat ap-
Figure 1 Decision analysis model of the treatment paths associated with advanced breast cancer therapy. Only the path for
patients receiving Letrozole is shown but the pathway for megestrol acetate would be identical. Prog: progression; SAE: severe
adverse event.
Figure 2 Health states in the advanced breast cancer model and probable movements between the health states. Note that for
clarity paths from the third-line hormone (3-line hormone) and chemotherapy 2 health states have been removed. Hypothetical
patients in the former health state can either stay in the same health state or, in the event of progression, move to chemotherapy 1,
observational care (observ.care), end-stage palliative care or death. For the chemotherapy 2 health state disease progression results
in movement to observ.care, end-stage palliative care or death.
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proach was employed to calculate the probability
of patients experiencing disease progression, a
treatment related severe adverse event, discontinu-
ing second-line therapy as well as the reason for
discontinuation, and the percentage of patients
dying in each 3-month period. For the letrozole
patients, only those receiving 2.5 mg daily, as dis-
tinct from those receiving 0.5 mg in the clinical
trial, were used for the analysis, because this was
the most effective dose [21]. Clinical data relating
to the second-line hormone health state in the
model are shown in Table 1.
Beyond second-line hormone therapy, informa-
tion on transition probabilities and treatment al-
ternatives was obtained from the literature and by
expert interview. This information is summarized
in Table 1 and described in detail by Nuijten et al.
[23]. For each health state published data from
randomized clinical trials were used to derive the
probability of having a response or a relapse to
the particular therapy, as well as the probability of
dying as a result of disease progression in the
health state. Average weighted values were deter-
mined from the appropriate literature where the
weighting was based on the number of patients in
each clinical trial. Since published trials lasted for
different periods of time the actuarial method [24]
was used to adjust probabilities to a cycle time of
3 months. For projection of the published clinical
data onto the model it was assumed that response
rates beyond second-line hormone therapy were
independent of the exact therapy used. For exam-
ple, probabilities for patients in the chemotherapy
1 health state were based on the general response
of patients to chemotherapeutic regimens, rather
than the response to a specific combination of
drugs. Treatment alternatives derived from the lit-
erature were validated by six breast cancer ex-
perts, two from Holland, three from the United
Kingdom, and one from Canada. In addition, a
panel of eight Canadian experts validated or mod-
ified treatment alternatives and provided missing
transition probabilities to reflect treatment prac-
tices for advanced breast cancer patients in Can-
ada. These experts were interviewed using the
modified Delphi method [25].
 
Resource Utilization
 
Resource utilization patterns were determined by
assessing direct medical resources for each health
state defined by the model. Resources were identi-
fied and quantified by the eight Canadian expert
interviews. Among the resources assessed were
outpatient care, including drug therapy, consulta-
tions (physicians and allied health care workers)
and laboratory tests and procedures, and inpatient
care, which included hospitalization and physician
consultations. Four of the experts provided infor-
mation on health care utilization associated with
the treatment of severe adverse events during sec-
ond-line hormone therapy.
 
Costing
 
A cost for each health state was determined by ap-
plying unit costs to the resources associated with
each state. All costs were expressed in 1996 Cana-
dian dollars and costing was accomplished using
unit prices from the Province of Ontario. The
costs for outpatient drugs were obtained either
from the Ontario Drug Benefit Formulary/Com-
parative Drug Index or, for those drugs not listed
in the formulary, using case costing data from the
Ottawa General Hospital. Outpatient physician
consultation fees were obtained from the Ontario
Schedule of Benefits, as were the costs for outpa-
tient laboratory tests and procedures, although in
this case some costs were also obtained from the
 
Table 1
 
Clinical parameters and data sources for
health states
 
Clinical Parameters % of patients/duration Data Source*
Second-line hormone
therapy health state AR/BC2 trial
[21]Treatment-related SAEs
 
†
 
letrozole 0
megestrol 12.2
Patients with no progression
after 3 months
letrozole 60.6
megestrol 58.2
Patients with no treatment
failure after 1.5 years
letrozole 17.8
megestrol 6.9
Third-line hormone therapy
health state [29–31] & 
Delphi panelPatients responding 55
Duration of response
(months)
7.3
Median survival (months) 16
First-line chemotherapy
health state [32–39] &
Delphi panelPatients responding 83
Duration of response
(months)
6.9
Median survival (months) 14.5
Second-line chemotherapy
health state [14,34,35,39] &
Delphi panelPatients responding 61
Duration of response (months) 4.8
Median survival (months) 9.1
 
*Data sources used to derive information on transition probabilities
for each health state
 
†
 
Severe adverse events
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Ottawa General Hospital. For inpatient care, hos-
pitalization was estimated using a per diem rate
calculated as an average from several Ontario hos-
pitals. Individual hospital rates were obtained
from the Ontario Ministry of Health and physi-
cian fees for inpatient care were derived from the
Ontario Schedule of Benefits. For the primary
analysis the cost of letrozole 2.5 mg was $4.95,
while for megestrol acetate 160 mg the cost was
$3.63, the generic price of this drug in Canada.
 
Cost-Effectiveness Analysis
 
The model was used to determine incremental
cost-effectiveness ratios for the treatment of ad-
vanced breast cancer in Canada with letrozole 2.5
mg. To determine the ratios, average per patient
treatment costs and the average patient clinical
outcomes were determined for both treatment
arms by a foldback analysis of the complete model
[26]. Incremental cost-effectiveness ratios (CE ra-
tio) were determined in the following manner:
(1) 
where C
 
L
 
 and C
 
M
 
 are the total treatment costs for
patients who initially received letrozole 2.5 mg or
megestrol acetate 160 mg, respectively, and E
 
L
 
 and
E
 
M
 
 the mean survival time or time without pro-
gression for the same treatment groups. The ratios
were expressed in terms of the cost per year of life
gained or the cost per month without progression.
 
Sensitivity Analyses
 
Sensitivity analyses were designed to test the stabil-
ity of the clinical and economic conclusions derived
from the model. Significant transition probabilities
were varied within the model and subsequent effects
on the cost-effectiveness ratios calculated. In partic-
ular, probabilities governing progression without an
adverse event within 3 months of initial therapy or
after 3 months of therapy for both letrozole- and
megestrol acetate-treated patients were varied. In
both cases the data defining the range for the anal-
ysis was based on minimum and maximum proba-
bilities from the clinical trial. The trial data indi-
cated that the probability of progression after 3
months of second-line therapy varied per 3-month
cycle. For the primary analysis this probability
was assumed to remain constant over time. How-
ever, a sensitivity analysis, incorporating ranges
defined by the minimum and maximum probabili-
ties of progression per cycle, tested the impact of
this variability on the cost-effectiveness ratio.
Probabilities for some variables were also varied
CE ratio CL CM–( ) EL EM–( )⁄=
 
between the minimum and maximum values re-
corded by the different experts. In a second series
of analyses, major cost drivers in health states
(hospitalization, drugs and adverse events) were
varied by 
 

 
20%.
 
Results
 
The model constructed for this study simulated
the long-term treatment of advanced breast cancer
in postmenopausal women in Canada, incorporat-
ing 25 cycles, each of a 3-month duration, for a
total period of 6.3 years. The 25 cycle, 6.3-year
cut-off was chosen because at this point only 1%
of the patients were still alive.
Table 2 shows the average projected long-term
clinical outcomes obtained for each virtual cohort,
when the second-line hormone therapy results were
incorporated into the model simulating long-term
care of these patients. Although the model was de-
signed to cover 6.3 years, mean survival time for
patients who initially received letrozole 2.5 mg was
28.26 months, compared to 25.74 months for the
megestrol acetate 160 mg patients. The mean time
to progression, calculated as a cumulative time over
all health states, was 19 months for the letrozole
2.5 mg patients and 16.5 months for those patients
initially receiving megestrol acetate 160 mg.
Resource utilization patterns derived from the
model are summarized in Table 3 with informa-
tion for five of the seven health states shown. The
results indicate that patients receiving letrozole
2.5 mg in second-line hormone therapy, who sub-
sequently go on to receive third-line hormone
therapy, were all assumed to receive megestrol ac-
etate 160 mg in this health state. Physician consul-
tations were common for all patients in each
health state but hospitalization was restricted to a
small number of patients, except in the end-stage
palliative care health state.
An average patient cost for the disease was de-
termined by calculating patient time spent in each
health state and applying health state costs to the
 
Table 2
 
Clinical outcomes for patients receiving letrozole 
2.5 mg or megestrol acetate 160 mg*
 
Second-line therapy
Outcome Letrozole
Megestrol
acetate
Mean survival time (months) 28.26 25.74
Two-year survival (% of patients) 52.9 44.5
Time without progression (months) 19.0 16.5
Duration of therapy (months) 12.3 9.8
 
*Long-term outcomes derived from the complete model.
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time spent (Table 4). The direct medical costs for
both treatment groups were similar with the total
cost for the letrozole 2.5 mg patient group slightly
higher than that of the megestrol acetate 160 mg
patients ($1061 difference). Within both groups
the major cost driver was medication which com-
prised 42% and 38% of the final costs for the
letrozole 2.5 mg and megestrol patients, respec-
tively. Hospitalization was the next most signifi-
cant cost driver (35% of total cost in both treat-
ment groups).
Incremental cost-effectiveness ratios were cal-
culated to link the clinical and economic model
outcomes. Incremental ratios were expressed in
two forms, calculated in both cases for patients
taking letrozole 2.5 mg with respect to those tak-
ing megestrol acetate 160 mg. When the calcula-
tion was based on life-years gained by taking let-
rozole 2.5 mg (0.3 years increased survival time
for patients taking letrozole 2.5 mg, compared to
those taking megestrol acetate 160 mg) the cost-
effectiveness ratio was $5051 per life-year gained.
Alternatively, when the incremental ratio was ex-
pressed in terms of the time without progression,
the ratio was $424.40 per month without progres-
sion for the letrozole 2.5 mg population.
Because of the complexity of the model, several
sensitivity analyses were carried out to test the ro-
bustness of the results. When the cost of hospital-
ization was varied by 
 

 
20% there was only a 1%
variation in the cost-effectiveness ratio (Table 5).
However, when the cost of adverse events was
varied by 
 

 
20% the cost-effectiveness ratio for
letrozole 2.5 mg varied by 
 

 
7.8%, a reflection of
the impact of adverse events on the overall cost of
care with megestrol acetate 160 mg. There was
only an 8% to 2.6% change in the ratio when che-
 
Table 3
 
Resource utilization in different health states
 
Health state
Resource Second-line hormone Third-line hormone Chemo 1 Chemo 2 End-stage
Drugs* Letrozole (100%) Megestrol (100%) CMF (40%) Adriamycin (50%) Morphine (64%)
Morphine (26%) Arimidex (63%) CAF (25%) Docetaxel (19%)
Naproxen (20%) Morphine (49%) CEF (23%) Paclitaxel (18%)
Codeine (14%) Naproxen (28%) Zofran (56%) Morphine (44%)
Dexamethasone (39%) Zofran (51%)
Morphine (38%)
Consultations* Oncologist (93%) Oncologist (93%) Oncologist (100%) Oncologist (100%) Oncologist (47%)
GP (58%) GP (58%) GP (49%) GP (48%) GP (46%)
Radio-oncologist
(27%)
Radio-oncologist
(37%)
Radio-oncologist
(23%)
Radio-oncologist
(25%)
Palliative care
(35%)
Lab tests/procedures*
Biochemistry 91% 91% 91% 91% 18%
Blood tests 89% 89% 91% 91% 30%
Bone scintigraphy 57% 61% 38% 38% 0%
Ultrasound 19% 42% 52% 53% 1%
Chest X-ray 44% 34% 11% 11% 1%
Bone X-ray 27% 25% 23% 24% 1%
Hospitalization
General medicine 2% (9 days)
 
†
 
3% (9.3 days) 1% (8.5 days) 1% (8 days) 2% (21 days)
Oncology 4% (5 days) 10% (10 days) 11% (8 days) 14% (8.5 days) 26% (13 days)
Palliative care 0% 0% 0% 0% 45% (20.5 days)
 
CMF 
 

 
 cyclophosphamide, methotrexate, 5-fluorouracil; CAF 
 

 
 cyclophosphamide, adriamycin, 5-fluorouracil; CEF 
 

 
 cyclophosphamide, epirubicin, 5-fluorou-
racil.
*Based on an outpatient setting.
 
†
 
Average length of stay for those patients hospitalized.
 
Table 4
 
Total direct per patient treatment costs 
($CAN,1996)
 
Discounted treatment costs*
Component Letrozole Megestrol
Medication
Hormones 2630.61 1541.00
Chemotherapy 3994.52 4026.30
Other 1734.78 1671.04
Total 8359.98 (41.6%)
 
†
 
7238.34 (38.1%)
Consultations
Physician 1573.96 1475.17
Paramedical care 846.49 824.98
Total 2420.46 (12.1%) 2300.15 (12.1%)
Procedures/tests
Diagnostic/therapeutic
tests 1654.62 1541.91
Radiotherapy 801.03 740.41
Blood transfusions 31.69 32.18
Total 2487.35 (12.4%) 2314.50 (12.2%)
Hospitalization 6800.22 (33.9%) 6750.73 (35.5%)
Adverse events 0 (0%) 403.04 (2.1%)
Total direct medical
costs 20068.00 19006.76
 
*Costs were discounted at 5% annually.
 
†
 
Percentages determined with respect to the total cost.
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motherapy costs were varied from their minimum
to maximum values (Table 5).
In the base case analysis, the probability of hav-
ing a progression (without a serious adverse event,
or SAE) within 3 months of second-line hormone
therapy was 0.394 for letrozole 2.5 mg and 0.352
for megestrol acetate 160 mg (Table 1). Variation
of the probability of progression for letrozole 2.5
mg from 0.321 to 0.468 changed the incremental
cost-effectiveness ratio from $4558 to $6163, but
treatment with letrozole remained cost-effective
compared to megestrol. However, when the prob-
ability for progression with megestrol was varied
(0.282–0.420) treatment with this drug became
clinically and economically dominant over letro-
zole 2.5 mg at the lowest probability value (0.282).
There were also large changes in the cost-effective-
ness ratio when the probabilities of progression
after 3 months were varied. For letrozole 2.5 mg,
when the probability varied from 0.139 to 0.583,
the mean patient survival time decreased from 2.8
years to 1.7 years and the cost-effectiveness ratio
went from $5506 per life-year gained to a situa-
tion where megestrol acetate 160 mg was clini-
cally and economically dominant at the higher
probability value. Similarly, when the probability of
progression with megestrol acetate after 3 months
was varied from 0.600 to 0.318, the incremental
cost-effectiveness for letrozole decreased from $2820
to a situation in which megestrol acetate was the
more dominant drug.
When the response rates to therapy were in-
creased or decreased in the third-line hormone
health state or in either of the two chemotherapy
health states, there was little or no subsequent
change in the cost-effectiveness ratio for letrozole
2.5 mg (results not shown). Hence the incremental
cost-effectiveness ratio for letrozole 2.5 mg was
mainly sensitive to efficacy changes in the second-
line hormone treatment phase of the disease.
 
Discussion
 
In this study clinical and economic outcomes were
compared in advanced breast cancer patients initiat-
ing second-line hormone therapy with either letrozole
2.5 mg or megestrol acetate 160 mg. The study was
not restricted to outcomes during second-line therapy
alone but followed patients through subsequent treat-
ment options to eventual death, and as such provides
an estimate of the economic burden associated with
the treatment of advanced metastatic breast cancer
patients in Canada. Modeling studies of this nature
have limitations since the results are at best a repre-
sentation of what might be found in clinical practice.
Limitations are due to a number of factors, including
reliance on expert opinion for resource utilization in-
formation and the derivation of probabilities for clin-
ical events from published results of clinical trials.
Clinical trials have a low external validity and be-
cause treatments are protocol driven the clinical re-
sults may not reflect actual day-to-day treatment of
advanced cancer patients. Nevertheless, a model does
provide a mechanism for the determination of long-
term average patient outcomes.
Given the drawbacks associated with this type
of study design an extensive validation process
and sensitivity analysis was performed. The as-
sumptions used to define the main characteristics
of the model (model structure/treatment pattern,
cycle time, health states, comparator, perspective)
and the findings of the study were validated by ex-
pert opinion and the literature. The reliability of
the model was assessed by comparing the out-
comes of the model with existing data from the lit-
erature and the updated AR/BC2 clinical trial
data. In the most recent follow-up data from the
trial (status as of 31 May 1997) patient survival
was estimated at approximately 2 years (21–25
months, depending on the treatment arm). In ad-
dition, the 2-year survival figures for letrozole-
and megestrol acetate-treated patients from the
extended AR/BC2 trial were 56% and 46%, re-
spectively, while the model yielded survival rates
of 46% and 37%. While there is a substantial dif-
ference in the absolute survival values between the
real and modeled outcomes, the difference in sur-
 
Table 5
 
Sensitivity analyses on the incremental cost-
effectiveness ratio for letrozole
 
Variable Range
Cost-effectiveness ratio
(cost $CAN) per year
of life gained
Primary analysis 5051
Hospitalization per diem $388–582* 5004–5099
Chemotherapy $244–8130
 
†
 
4643–5182
SAE costs
 
‡
 
$1518–2277 4659–5444
Probabilities
Letrozole
Progression within
3 months 0.321–0.468 4558–6163
Progression after
3 months 0.139–0.583 5506-Megestrol
dominantMegestrol
Progression within
3 months 0.282–0.42 Megestrol
dominant-2359
Progression after
3 months
0.318–0.6 Megestrol
dominant-2820
 
*Represents a 
 

 
20% variation in the per diem rate.
 
†
 
Minimum and maximum costs from the analysis.
 
‡
 
SAE, severe adverse events; In this analysis SAE costs were varied by 
 

 
20%.
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vival remains essentially the same at approxi-
mately 10% for both drugs.
Other studies support the validity of the model.
In particular, published values for the median sur-
vival time for patients with advanced breast can-
cer are approximately 2 years [10,18]. This com-
pares favorably with the mean survival times of
2.1 years for letrozole 2.5 mg and 1.9 years for
megestrol acetate 160 mg calculated from the
model. The economic outcomes predicted by the
model also compare favorably with data in the lit-
erature. The total per patient treatment costs de-
termined in this study were $20,068 and $19,007
for patients initially receiving second-line hor-
mone therapy with letrozole 2.5 mg or megestrol
acetate 160 mg, respectively. In a retrospective
analysis of patient charts in the United Kingdom,
Richards et al. [18] calculated the mean per pa-
tient cost (£1991) for advanced breast cancer pa-
tients at £7620 ($17,146 CAN), close to the figure
determined here. In addition, findings have been
tested by sensitivity analyses and results compared
to other studies. The results of these analyses indi-
cate that clinical efficacy and safety play signifi-
cant roles in determining the final outcomes of the
model. This is consistent with the findings of Hut-
ton et al. [13] who noted that response rate is a
key parameter determining the utility of chemo-
therapy.
On the basis of the model, patients initially re-
ceiving letrozole in second-line therapy had a 10%
increase in survival and a 15% increase in time to
progression. For the latter, cumulatively calculated
over the different treatment options, letrozole pa-
tients had a mean time without progression of 19
months. Therefore patients receiving letrozole in
second-line therapy have improved clinical out-
comes compared to patients receiving megestrol.
The cost-effectiveness ratio for letrozole 2.5 mg
($5051 per life-year gained) represents the increased
cost to the Ministry of Health for the better clini-
cal outcomes associated with the care of advanced
breast cancer patients with letrozole 2.5 mg, com-
pared to their care with megestrol acetate. In gen-
eral terms, a cost-effectiveness ratio of $5051 is
excellent value when compared to other presently
funded medical interventions such as renal dialysis
where the ratio varies from $20,000 to $74,000
(1993 $US) [27]. In addition, this ratio is highly
favorable when compared to other cancer thera-
pies. The cost-effectiveness ratio for postsurgical
chemotherapy for premenopausal women with
breast cancer is $18,000 (1993 $US) per life-year
gained [27] and Covens et al. [28] calculated a ra-
tio of $20,355 (1993, $CAN) per life-year gained
for the treatment of advanced ovarian cancer with
paclitaxel and cisplatin.
In conclusion, the present study suggests that
letrozole 2.5 mg may be a suitable alternative to
megestrol acetate 160 mg as second-line hormone
therapy in the treatment of advanced breast cancer
patients in Canada. Patients receiving letrozole 2.5
mg have better clinical outcomes than megestrol
acetate 160 mg patients and this increased benefit
comes at a minimal and acceptable cost. In general
the model proved insensitive to most of the uncer-
tain variables, and was mainly sensitive to the effi-
cacy parameters with second-line hormone ther-
apy, which suggests that outcomes derived from
this study should be judged cautiously.
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